AI-generated · cited to primary sources · not investment advice · How we research
Dr Agarwal's Hea
Our verdict on Dr Agarwal's Hea isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company successfully relocated and upgraded its Whitefield, Bangalore facility in August 2024 from a secondary to a tertiary center, resulting in a 20% growth in revenue per month.
“recording a growth of more than 20% since we have relocated to this new 20,000”
The cash flow statement for the subsidiary (AEHL) confirms the receipt of INR 70 Cr. from the issue of equity share capital during H1 FY26.
“Proceeds from issue of equity share capital (including employee stock options”
See the full cited Management analysis of Dr Agarwal's Hea
How durable is the business?
Surgical revenues remain the dominant pillar, with volumes growing 28% year-on-year for the full year. High-end cataract surgeries increased their contribution to the mix.
“in FY '25, the surgical revenues form the main pillar of our service offering, contributing to”
The company is aggressively expanding its footprint, adding 59 facilities in FY25 and targeting another 55-60 in FY26, with a focus on the southern states and Maharashtra.
“Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities”
See the full cited Business Model analysis of Dr Agarwal's Hea
Where does growth come from?
The company is building a 'Doctor Flywheel' by rapidly hiring and retaining specialists, which acts as a competitive moat in the healthcare industry.
“908 Doctors and 2,052 Paramedical Staff”
The adoption of high-end laser-assisted (Femto) cataract surgeries is accelerating, with contribution to total cataract volume rising from 19.2% in FY24 to 22.5% in FY25.
“increase in contribution coming in from high-end cataract surgeries, which has moved up from 19.2% in FY '24 to 22.5% in FY '25”
See the full cited Future Growth analysis of Dr Agarwal's Hea
What could break the thesis?
Geographic concentration remains high but is gradually diversifying. Revenue from the South region decreased from 64% to 63.1% of the payor mix, and the company is aggressively expanding into the North (Delhi NCR, Punjab) and West (Gujarat).
“Approximately 65% of our Indian network is present in cities beyond the top metropolitan areas”
The risk is intensifying as the company plans to accelerate expansion to 55-60 new facilities in FY26 (up from 59 in FY25), with a significant capex of INR 310 crores.
“Looking ahead, in FY '26, we are targeting a launch of 55 to 60 facilities”
See the full cited Risk analysis of Dr Agarwal's Hea
Read the full thesis on Dr Agarwal's Hea
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.